You are here: Industry Insights > SMC

News List

Thermoset Molding Compound Market Size, Impacted by COVID-19, to Reach US$ 4.6 Billion in 2026, Says Stratview Research prnewswire
January 19, 2022
Stratview Research announces the launch of a new research report on Thermoset Molding Compound Market by End-Use Industry Type (Transportation, Construction, Consumer Goods, Electrical & Electronics...
Scottish Medicines Consortium approves three cancer drugs for NHS use Pharmaceutical-Technology
December 20, 2021
The Scottish Medicines Consortium (SMC) has approved three drugs for use on the National Health Service (NHS) Scotland to treat advanced ovarian, bowel cancer and Waldenström’s macroglobulinaemia.
UCB’s BIMZELX (bimekizumab) receives expedited acceptance from Scottish Medicines Consortium (SMC) for the treatment of plaque psoriasis FirstWordPharma
November 10, 2021
Bimekizumab has received acceptance through the Scottish Medicines Consortium’s (SMC) fast- track process1
SMC approves Bavencio for bladder cancer pharmatimes
August 11, 2021
Merck and Pfizer’s Bavencio (avelumab) has been approved by the Scottish Medicines Consortium (SMC) for use via NHS Scotland as a first-line maintenance treatment for adult patients with locally advanced or metastatic urothelial carcinoma ...
Tecentriq, Kesimpta lead latest SMC decisions pharmatimes
July 14, 2021
The Scottish Medicines Consortium (SMC) has accepted three new medicines for use by NHS Scotland and rejected one in its July 2021 decisions.
SMC backs five new medicines for NHS use pharmatimes
June 09, 2021
The Scottish Medicines Consortium (SMC) has accepted five new medicines for use by NHS Scotland in its June 2021 decisions.
SMC endorses Alexion’s Ultomiris pharmatimes
May 12, 2021
The Scottish Medicines Consortium (SMC) has accepted a treatment for an ultra-rare disease that can cause progressive injury to vital organs via damage to the walls of blood vessels and blood clots in its May decisions.
Four medicines accepted for use by NHS Scotland pharmatimes
April 13, 2021
The Scottish Medicines Consortium (SMC) has approved NHS funding for four new medicines, including treatments for multiple myeloma and severe migraine in its April 2020 decisions.
SMC accepts Zolgensma and Rozlytrek for use by NHS Scotland pharmatimes
March 10, 2021
The Scottish Medicines Consortium (SMC) has accepted Novartis Gene Therapies' Zolgensma and Genentech’s Rozlytrek for use by NHS Scotland as part of its March 2021 decisions.
Once daily multiple sclerosis treatment approved for use in Scotland europeanpharmaceuticalreview
February 10, 2021
The Scottish Medicines Consortium has approved Zeposia® (ozanimod) for use in relapsing remitting multiple sclerosis patients.

Previous page 1 2 3 4 Next page